Pasar al contenido principal

ALMA: Etiqueta visual intuitiva para la verificación y calidad de alimentos por el binomio RMN e IA

PTQ2024-013941

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Recursos Humanos
Subprograma Subprograma Estatal de Formación, Atracción y Retención del Talento Investigador e Innovador
Convocatoria Torres Quevedo
Año convocatoria 2024
Plan Estatal 2024-2027 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario MANSCITECH S.L.

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NLRP3 haploinsufficiency unmasks a compensatory NLRP1-NLRP3 interaction that drives accelerated aging in mice

  • Muela-Zarzuela, Inés
  • Alcocer-Gómez, Elisabet
  • Suarez-Rivero, Juan M.
  • Low, Evon
  • Ishaq, Abbas
  • Azkargorta, Mikel
  • Luque-Sierra, Amparo
  • Martin, Franz
  • Elortza, Félix
  • Astorga-Gamaza, Antonio
  • Antón, Rosa
  • Bali, Sofía
  • Tamargo-Azpilicueta, Joaquin
  • Guerra-Castellano, Alejandra
  • Díaz-Moreno, Irene
  • Joachimiak, Lukasz A.
  • Oroz, Javier
  • Ruiz-Cabello, Jesús
  • von Zglinicki, Thomas
  • Sanz, Alberto
  • Cordero, Mario D.
The NLRP3 inflammasome has been implicated in a wide range of human diseases, including cardiovascular, metabolic, neurodegenerative (such as Alzheimer's disease), and other age-related conditions. This has positioned NLRP3 as a promising pharmacological target. Numerous studies have shown that complete NLRP3 ablation can prevent or mitigate these diseases. However, total elimination of NLRP3 is not a feasible therapeutic strategy for the millions of patients affected by these degenerative disorders. Consequently, drug development efforts have focused on partial inhibition of NLRP3 using compounds that reduce its expression or activity. Paradoxically, although many studies have used Nlrp3 knockout mouse models, Nlrp3 haploinsufficient mice-more representative of the effects of pharmacological inhibition-are rarely included and remain poorly characterized. Here, we report the long-term effects of Nlrp3 haploinsufficiency during aging. Although no overt differences were observed in early life, by 16 months of age, Nlrp3 heterozygous mice exhibited signs of accelerated inflammatory aging, driven by compensatory overexpression of NLRP1. Mechanistic studies provide evidence of a previously unidentified interaction between NLRP1 and NLRP3, forming a hybrid inflammasome that drives NLRP1-mediated inflammatory overactivation when NLRP3 expression is reduced. Accordingly, anti-inflammatory treatment provided notable but moderate improvement of the inflammatory phenotype, whereas genetic inhibition of Nlrp1 more consistently reduced inflammation and extended health span. Our findings reveal a previously unidentified compensatory interaction between NLRP1 and NLRP3 and suggest that multiinflammasome inhibition may offer a more effective strategy for treating aging and age-related diseases., This study was supported by grant PI21/01656 from the Instituto de Salud Carlos III (Spain), grant EMC21_00033 from the EMERGIA programme of the Junta de Andalucía, and grant CNS2024-154939 from the Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación. Funding for open access publication was provided by the Universidad Pablo de Olavide/CBUA. J.R.-C . is funded by grant PID2021-123238OB- I00 and PID2024-155807OB- C 21 funded by the MCIN/AEI and from the Fundación contra la Hipertensión Pulmonar (Project Empathy). I.D.-M. is funded by grant PID2024-157414NB- I00 funded by the MICIU/AEI/10.13039/501100011033 and by ERDF/EU, Ramon Areces Foundation (LEUCYTO-FRA2025- MAR), grant FPU22/01094 funded by MICIU/AEI/10.13039/501100011033 and by ESF+ to J.T.-A., and grant PTQ2024-013941 funded by MICIU/AEI/10.13039/501100011033 to A.G.-C . J.O. is supported by the grants PID2019-109276RA- I00 and PID2022-142382OB- I00 funded by MCIN/AEI/10.13039/501100011033 and by FEDER A way to make Europe and by donations from the Spanish and Mexican Ondine Associations. J.O. was a recipient of a Leonardo Grant from the Spanish BBVA Foundation (BBM_TRA_0203) and a Ramón y Cajal Fellow of the Spanish AEI-Ministry of Science and Innovation (RYC2018-026042- I funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”)., Peer reviewed